Polycythemia Vera clinical trials
The registry lists 227 studies for Polycythemia Vera across more than 10 countries. 52 are recruiting or about to start. Per ClinicalTrials.gov, last updated 2026-09-24.
Status
- Completed
- 113
- Recruiting
- 41
- Terminated
- 26
- Active, not recruiting
- 16
- Not yet recruiting
- 10
- Status unknown
- 10
Phase
- Phase 2
- 99
- Phase 1
- 50
- Phase 3
- 31
- Phase 4
- 3
- Early Phase 1
- 2
Where
- United States
- 135
- Italy
- 47
- France
- 39
- Germany
- 39
- Canada
- 35
- United Kingdom
- 33
Who runs them
Novartis Pharmaceuticals (19) · M.D. Anderson Cancer Center (10) · National Cancer Institute (NCI) (10) · Incyte Corporation (10) · Sierra Oncology LLC - a GSK company (9) · Ronald Hoffman (5) · FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS (5) · John Mascarenhas (5)
Studies
Recruiting first, then most recently updated. Showing 50 of 227 — search for more.
- A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative NeoplasmsRecruitingNCT07469891Phase 12 countries
- Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative NeoplasmsRecruitingNCT04282187Phase 21 country
- INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)RecruitingNCT07429266Phase 33 countries
- A Study of Rusfertide in Japanese Adults With Polycythemia VeraRecruitingNCT07648030Phase 21 country
- A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)RecruitingNCT06661915Phase 21 country
- A Study of Rusfertide in Adults With Polycythemia Vera in ChinaNot yet recruitingNCT07765602Phase 2
- Study of BEBT-507 Injection in Subjects With Polycythemia Vera (PV)RecruitingNCT07012109Phase 11 country
- Phase IIa Study of Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia VeraRecruitingNCT07232290Phase 21 country
- Functional and Phenotypic Characterization of Monocytes in Myeloproliferative SyndromesRecruitingNCT06361641Not applicable1 country
- Standardized Documentation and Assessments for Polycythemia Vera: A Quality Improvement InitiativeNot yet recruitingNCT07734272Not applicable
- A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025)Not yet recruitingNCT07722611Phase 2/3
- Study of INCA036978 in Participants With Myeloproliferative NeoplasmsRecruitingNCT07441694Phase 111 countries
- Observational Study on the Use of Ropeginterferon Alfa-2b in Polycythemia Vera (ROPEG-PV)RecruitingNCT065060842 countries
- A ELN-Multicenter Study on Phenotypic Evolution and Clinical OutcomesRecruitingNCT072037685 countries
- Registry of Older Patients With CancerRecruitingNCT011378251 country
- A Clinical Study of Gecacitinib Combined With Pegylated Interferon in Patients With PVRecruitingNCT07445893Not applicable1 country
- MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia VeraRecruitingNCT04116502Phase 31 country
- Study of ZE74-0282 for Patients With JAK2 V617F Positive Blood CancersNot yet recruitingNCT07529951Phase 1
- ENERGIA: Personalized Exercise Program for Fatigue in Patients With Myeloproliferative Neoplasms and Chronic Myeloid LeukemiaNot yet recruitingNCT07518940Not applicable1 country
- A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)RecruitingNCT06351631Phase 36 countries
- Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative NeoplasmsRecruitingNCT06063486Phase 21 country
- Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia VeraRecruitingNCT06093672Phase 316 countries
- AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative NeoplasmsRecruitingNCT05198960Phase 31 country
- An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative NeoplasmsRecruitingNCT05123365Phase 1/21 country
- MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)RecruitingNCT073622251 country
- WELL-MPN: A Digital Lifestyle App for Patients With MPNsNot yet recruitingNCT07349134Not applicable1 country
- Potential Biological and Physiological Determinants for Exercice in Patients With Polycythemia VeraNot yet recruitingNCT07341048Not applicable1 country
- Ropeginterferon Alfa-2b in Patients With Polycythemia Vera (PV) Without Symptomatic SplenomegalyRecruitingNCT067430351 country
- Ruxolitinib in Thrombocythemia and Polycythemia VeraRecruitingNCT04644211Phase 21 country
- MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) TrialRecruitingNCT06541249Phase 21 country
- Blood Viscosity in Polycythemia PatientsRecruitingNCT064210251 country
- Managed Access Programs for INC424, RuxolitinibAvailableNCT04745637
- Two Step Haplo With Radiation ConditioningRecruitingNCT05031897Phase 21 country
- Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic CancerRecruitingNCT011376431 country
- A Study of GLB-001 in Patients With Myeloid MalignanciesRecruitingNCT06378437Phase 11 country
- Prevalence Of Germline Gene Mutations In Patients With Myeloproliferative Neoplasms With Family HistoryNot yet recruitingNCT06923670Not applicable
- A Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 9MW3011 in Patients With Polycythemia VeraRecruitingNCT06752746Phase 11 country
- EVAluation of Erythrocytosis PRospEctive Cohort STudyNot yet recruitingNCT067858701 country
- Efficacy and Safety of Peginterferon in ET and PV.RecruitingNCT06734637Not applicable1 country
- Ruxolitinib in Primary Myelofibrosis and Secondary to Essential Thrombocythemia or Polycythemia VeraRecruitingNCT065164061 country
- Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET PatientsRecruitingNCT04655092Phase 31 country
- A Post-Marketing Surveillance Study to Assess the Safety of Fedratinib in Korean Patients With MyelofibrosisRecruitingNCT060738471 country
- Myeloproliferative Neoplasms (MPNs) Patient RegistryRecruitingNCT027602381 country
- Myeloproliferative Neoplastic Diseases Observatory From BrestRecruitingNCT028972971 country
- Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PVRecruitingNCT05870475Phase 21 country
- Real-world Ruxolitinib Experience in PVNot yet recruitingNCT06251102
- Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 InhibitionRecruitingNCT06218628Phase 11 country
- Real World Evidence of Fedratinib Effectiveness in MFRecruitingNCT058839041 country
- Hematocrit to Hemoglobin Ratio and Red Blood Cell Distribution Width in Polycythemia Vera and Secondary Erythrocytosis.RecruitingNCT059930651 country
- Asian Myeloproliferative Neoplasm (MPN) RegistryRecruitingNCT058827731 country